Brief: Brii Bio Presents New Data From Its Ongoing Phase 2 Chronic Hepatitis B Trials
07/06/2024 12:37
June 7 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIO PRESENTS NEW DATA FROM ITS ONGOING PHASE 2
CHRONIC
HEPATITIS B TRIALS AT EASL™ CONGRESS 2024
Source text for Eikon: ID:nPn2NbFlva
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR